BI-9564 is primarily utilized in the field of cancer research due to its role as a selective inhibitor of BRD9, a protein involved in the regulation of gene expression. By inhibiting BRD9, BI-9564 helps researchers study the effects of disrupting specific pathways in cancer cells, particularly in cases of acute myeloid leukemia (AML) and other malignancies. This compound is valuable in preclinical studies for understanding the mechanisms of BRD9 and its potential as a therapeutic target. Its application extends to the development of novel cancer therapies by providing insights into the epigenetic regulation of cancer progression and resistance mechanisms.